T. Rowe Price Investment Management, Inc. Crispr Therapeutics Ag Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,683,026 shares of CRSP stock, worth $208 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
3,683,026
Previous 3,798,103
3.03%
Holding current value
$208 Million
Previous $129 Million
38.6%
% of portfolio
0.11%
Previous 0.09%
Shares
12 transactions
Others Institutions Holding CRSP
# of Institutions
529Shares Held
68.7MCall Options Held
3.79MPut Options Held
2.29M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$576 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$317 Million0.05% of portfolio
-
State Street Corp Boston, MA3.27MShares$185 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$161 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$157 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.42B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....